RNAi Market and Technologies Industry Report 2024, with Company Profiles of Major Players including Alnylam Pharmaceuticals, Novartis, Thermo Fisher Scientific and Revvity
23 août 2024 04h02 HE
|
Research and Markets
Dublin, Aug. 23, 2024 (GLOBE NEWSWIRE) -- The "RNAi Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.The global market for RNAi technology is estimated to...
ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer
30 juil. 2024 09h05 HE
|
ADARx Pharmaceuticals
ADARx Pharmaceuticals Appoints Ajim Tamboli, CFA as Chief Financial Officer
Wave Life Sciences Announces Upcoming Presentations Highlighting Novel siRNA Program in Obesity and Leadership in RNA Editing
12 juin 2024 08h30 HE
|
Wave Life Sciences USA, Inc.
Presentation at the Obesity & Weight Loss Drug Development Summit to review Real World Evidence for the GLP-1 class and the opportunity for Wave’s INHBE program as a best-in-class approach for...
Phio Pharmaceuticals Secures New Investor
17 mai 2024 09h00 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)
16 mai 2024 08h00 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., May 16, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
15 mai 2024 13h00 HE
|
Phio Pharmaceuticals Corp.
-PH-762 is Phio’s lead product candidate -Screening on the next cohort is on-going MARLBOROUGH, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage...
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
09 mai 2024 17h25 HE
|
Phio Pharmaceuticals Corp.
–Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762 –Three patients have been enrolled MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) --...
Global RNAi Therapeutics Market Analysis Report 2024-2028: Progress in Collaborations & Associated Deals Bodes Well for the Sector
01 mai 2024 09h16 HE
|
Research and Markets
Dublin, May 01, 2024 (GLOBE NEWSWIRE) -- The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19...
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
30 avr. 2024 07h30 HE
|
Phio Pharmaceuticals Corp.
MARLBOROUGH, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is...
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
22 avr. 2024 13h10 HE
|
Phio Pharmaceuticals Corp.
-Injection in murine tumors shows the compound is well tolerated -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma ...